sapablursen
Sponsors
Deciphera Pharmaceuticals Inc., Ionis Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd.
Conditions
Beta Thalassemia IntermediaPhlebotomy Dependent Polycythemia VeraPolycythemia Vera
Phase 2
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)
TerminatedNCT04059406
Start: 2020-09-24End: 2023-03-28Updated: 2025-02-18
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
CompletedNCT05143957
Start: 2021-12-30End: 2026-06-02Updated: 2026-07-09
Phase 3
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
RecruitingNCT07429266
Start: 2026-05-25End: 2031-01-01Target: 250Updated: 2026-09-08
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Not yet recruitingCTIS2025-524669-25-00
Target: 20Updated: 2026-08-21